



# Resource impact summary report

Resource impact

Published: 16 April 2025

[www.nice.org.uk](http://www.nice.org.uk)

# Contents

Resource impact summary report .....	3
Recommendation .....	3
Treatment options for the eligible population .....	3
Financial resource impact (cash items) .....	3
Capacity impact .....	4
Key information.....	4
About this resource impact summary report.....	4

# Resource impact summary report

This summary report is based on the NICE assumptions used in the [resource impact template](#). Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect local data and assumptions.

## Recommendation

NICE has recommended molnupiravir as an option for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test, only if:

- they have 1 or more risk factors for progression to severe COVID-19 (as defined in [section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19](#)) and
- nirmatrelvir plus ritonavir is contraindicated or unsuitable.

## Treatment options for the eligible population

The comparator treatment for the eligible population is nirmatrelvir plus ritonavir.

Molnupiravir and nirmatrelvir plus ritonavir are both administered orally.

For more information about the treatments, such as dose and average treatment duration, see the [resource impact template](#).

## Financial resource impact (cash items)

The list price for molnupiravir is £590 per pack containing 40 capsules.

Users can input the confidential price of molnupiravir and amend other variables in the [resource impact template](#).

The payment mechanism for the technology is determined by the responsible

commissioner and depends on the technology being classified as high cost.

- We expect the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £8,800 per 100,000 population, based on a population for England of 57.16 million people). This is because the technology is a further treatment option, the overall cost of treatment will be similar for this population and we do not think practice will change substantially as a result of this guidance.

For further analysis or to calculate the financial impact of cash items, see the [resource impact template](#).

## Capacity impact

To calculate the financial capacity impact from a commissioner (national) and provider (local) perspective, see the [resource impact template](#).

## Key information

Table 1 Key information

Time from publication to routine commissioning funding	90 days
Programme budgeting category	PBC 01x infectious diseases
Commissioner(s)	Integrated care boards
Provider(s)	Primary care providers and NHS hospital trusts.
Pathway position	Provided nirmatrelvir plus ritonavir is contraindicated or unsuitable

## About this resource impact summary report

This resource impact summary report accompanies the [NICE technology appraisal guidance on molnupiravir for treating COVID-19](#) and should be read with it.

ISBN: 978-1-4731-9330-7